Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

NCT06282458 · Completed

Last updated 2026-05-28

This clinical trial is testing different doses of the drug enobosarm in adults with muscle loss and obesity who are also taking a GLP-1 medication for weight management.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 168 people

Who can join Ages 60–100 · all sexes Healthy volunteers accepted.

Timeline Started 2024-04 · est. completion 2025-08

Where 14 sites · United States

What this study is testing ClinicalTrials.gov NCT06282458 ↗

Description as written by the study sponsor.

The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.

Treatments tested

Enobosarm Drug

Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.
Semaglutide also known as Wegovy Drug

Semaglutide for Chronic Weight Management

Main thing measured	The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days.
Sponsor	Veru Inc.
Conditions studied	Muscle Loss, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06282458 ↗